Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Zevra Therapeutics

Tracked across 3 events · 41 articles · First seen Jun 08, 2026 · Last active Aug 11, 2026

Sentiment
-7
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 50
Regulatory
Impact: Zevra Therapeutics has strengthened its intellectual property protection for MIPLYFFA by submitting a new patent for Orange Book listing, extending its exclusivity until 2041. This action aims to maximize the long-term value of the drug and support patients with Niemann-Pick disease type C.
Jun 08, 2026 · 6 articles
4 -70
Regulatory
On July 24, 2026, the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa,…
Impact: Zevra Therapeutics is the central entity, facing a 24% stock drop and a securities investigation following the CHMP's negative opinion on its lead drug arimoclomol. The company plans to request a re-examination and continues its Expanded Access Program.
Jul 24, 2026 · 29 articles
3 0
Business
Impact: Commercial product MIPLYFFA included in acquired portfolio.
Jul 14, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Zevra Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.